{"id":37304,"date":"2026-05-06T10:18:00","date_gmt":"2026-05-06T14:18:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37304"},"modified":"2026-03-10T17:03:07","modified_gmt":"2026-03-10T21:03:07","slug":"win-the-specialty-pharmacy-contract-before-the-drug-patent-expires-a-business-development-guide-for-biopharma-commercial-market-access-vendors","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/win-the-specialty-pharmacy-contract-before-the-drug-patent-expires-a-business-development-guide-for-biopharma-commercial-market-access-vendors\/","title":{"rendered":"Win the Specialty Pharmacy Contract Before the Drug Patent Expires: A Business Development Guide for Biopharma Commercial & Market Access Vendors"},"content":{"rendered":"\n

The Clock You Are Ignoring<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every branded drug in the specialty channel has an expiration date that has nothing to do with chemistry. It is the patent expiration date, and for commercial and market access vendors, it is the most important number in your pipeline.<\/p>\n\n\n\n

When a drug loses exclusivity (LOE) – meaning its patents expire and generic or biosimilar competition enters the market – the commercial ecosystem around it contracts fast. Manufacturer budgets shrink. Hub programs get restructured or eliminated. Copay assistance programs disappear almost overnight because the manufacturer no longer has a margin incentive to fund them. Specialty pharmacies shift their dispensing behavior toward lower-cost alternatives.<\/p>\n\n\n\n

For vendors selling hub services, patient support programs, adherence platforms, prior authorization support, copay administration, or commercial analytics – the LOE event is not just a market signal. It is a deadline.<\/p>\n\n\n\n

The vendors who win long-term contracts and embedded relationships with specialty pharmacies are the ones who show up 18 to 36 months before that deadline, not after. This guide explains how to do that, who to target, what to say, and what intelligence tools to use to stay ahead of the curve.<\/p>\n\n\n\n

What LOE Actually Does to the Specialty Channel<\/strong><\/h2>\n\n\n\n

A branded specialty drug – say, an injectable biologic for a rare autoimmune condition – might carry a wholesale acquisition cost (WAC) of $40,000 to $120,000 per patient per year. The manufacturer funds a robust commercial infrastructure around that drug: a specialty pharmacy network with limited distribution, a hub program with patient access counselors, a copay assistance program capped at $10,000 to $15,000 per patient per year, and a reimbursement support team handling prior authorization appeals.<\/p>\n\n\n\n

That entire infrastructure exists because the margin supports it. The moment biosimilar or generic competition enters, price erosion begins. IQVIA research shows that branded biologics lose 30 to 40 percent of their unit market share within 12 months of biosimilar entry [1]. At that compression, the economics of hub programs, copay assistance, and limited distribution networks become unsustainable.<\/p>\n\n\n\n

What does the manufacturer do? They cut. Hub programs get consolidated. Specialty pharmacy network agreements get renegotiated at lower service fees. Copay assistance programs convert to patient assistance programs (PAPs) with income-based eligibility rather than broad commercial coverage. Data reporting requirements get scaled back.<\/p>\n\n\n\n

For vendors whose revenue depends on those program fees, a single LOE event can eliminate a meaningful revenue line. The answer is not to avoid drugs approaching LOE. The answer is to be positioned inside the next revenue cycle – the next product launch – before the current one ends.<\/p>\n\n\n\n

The 18-to-36-Month Window: Why It Exists<\/strong><\/h2>\n\n\n\n

The specialty pharmacy relationship cycle for a new drug typically follows a predictable sequence:<\/p>\n\n\n\n

    \n
  • 36-48 months pre-launch: Manufacturer selects hub partner, begins building the limited distribution network, identifies preferred specialty pharmacy partners.<\/li>\n\n\n\n
  • 18-24 months pre-launch: Network contracts finalized, data reporting specifications agreed, patient support program design locked.<\/li>\n\n\n\n
  • 12 months pre-launch: Specialty pharmacies complete onboarding, staff training begins, systems integrations tested.<\/li>\n\n\n\n
  • Launch: Commercial go-live.<\/li>\n<\/ul>\n\n\n\n

    When you map that cycle backward against patent expiration for an existing drug, you get the 18-to-36-month pre-LOE window. That is the period when the manufacturer team responsible for the next asset – the follow-on product, the indication extension, or the new molecular entity in the same therapeutic category – is in active vendor evaluation mode.<\/p>\n\n\n\n

    The vendor who already has a relationship with the specialty pharmacies dispensing the current product has a structural advantage in that evaluation. The specialty pharmacy can provide a warm reference. The vendor has demonstrated operational capability in that disease state. The manufacturer already has performance data on that vendor from the existing program.<\/p>\n\n\n\n

    That relationship does not build itself in 90 days. It requires a deliberate, multi-year business development strategy anchored to patent intelligence.<\/p>\n\n\n\n

    Mapping the Specialty Pharmacy Landscape<\/strong><\/h2>\n\n\n\n

    Before you can target specialty pharmacies strategically, you need to understand how the market is structured. It is not monolithic. The U.S. specialty pharmacy market has four tiers, each requiring a different BD approach.<\/p>\n\n\n\n

    The largest PBM-owned specialty pharmacies – Accredo (Cigna\/Evernorth), CVS Specialty, AllianceRx Walgreens Prime, and Optum Specialty – handle the majority of specialty drug dispensing volume by dollars. They have sophisticated data infrastructure, large patient populations across therapeutic categories, and integrated payer relationships that give them formulary influence. Getting a program contracted with any of these four is a significant commercial milestone.<\/p>\n\n\n\n

    Integrated health system specialty pharmacies – operated by academic medical centers and large IDNs like Mayo Clinic, Cleveland Clinic, and Vanderbilt University Medical Center – are growing. They have deep clinical relationships with prescribers in their systems and are increasingly preferred as limited distribution network partners for rare disease and oncology products, precisely because they can connect dispensing data to clinical outcomes in ways the retail-affiliated SPs cannot.<\/p>\n\n\n\n

    Independent specialty pharmacies – including category specialists like US Bioservices, BioMatrix (hemophilia), Orsini (neurological conditions), and Avita Pharmacy (rare disease) – hold preferred network status for specific therapeutic categories. A manufacturer building a limited distribution network for a gene therapy will almost certainly include one of these specialists.<\/p>\n\n\n\n

    Physician office dispensing, while more limited by state regulations, exists as a fourth channel primarily in oncology (oral oncolytics) and rheumatology. Your BD strategy should segment these tiers differently, because the vendors they evaluate, the contracts they sign, and the programs they run are structurally different.<\/p>\n\n\n\n

    What Vendors Are Actually Selling to Specialty Pharmacies Pre-LOE<\/strong><\/h2>\n\n\n\n

    The commercial and market access vendor category is broad. Here is what the market actually buys, and when the buying happens relative to LOE:<\/p>\n\n\n\n

    Hub Services and Patient Access Programs<\/strong><\/h4>\n\n\n\n

    These are contracted by manufacturers, not specialty pharmacies. But specialty pharmacies influence the selection. When a manufacturer’s BD team evaluates hub partners for a new product, they ask their preferred SP network which hub vendors they have the best operational history with. A hub vendor with zero presence in the specialty pharmacies serving the disease state of interest is at a significant disadvantage.<\/p>\n\n\n\n

    Adherence and Therapy Management Programs<\/strong><\/h4>\n\n\n\n

    These are purchased both by manufacturers (who fund them as part of hub programs) and directly by specialty pharmacies trying to differentiate their clinical services. Pre-LOE, specialty pharmacies serving patients on high-value branded drugs are motivated to invest in adherence technology because their dispensing fees and DIR-adjusted margins depend on demonstrating outcomes.<\/p>\n\n\n\n

    Analytics and Data Licensing<\/strong><\/h4>\n\n\n\n

    These are purchased by manufacturers who need SP-level dispensing data, and by specialty pharmacies that want to monetize their patient data assets in compliance with applicable regulations. The pre-LOE window is when manufacturers are especially motivated to purchase granular SP data: they need to understand patient population characteristics before LOE to defend their commercial program’s ROI.<\/p>\n\n\n\n

    Copay Assistance and Financial Toxicity Management Technology<\/strong><\/h4>\n\n\n\n

    Predominantly manufacturer-funded, but specialty pharmacies increasingly evaluate and recommend third-party platforms that integrate cleanly with their dispensing workflow. The pre-LOE period is when manufacturers are running their highest-volume copay programs, which means the operational stress on this infrastructure is highest and the value of better technology is most visible.<\/p>\n\n\n\n

    Prior Authorization Automation and Reimbursement Support<\/strong><\/h4>\n\n\n\n

    These are purchased by specialty pharmacies directly because they affect operational efficiency and patient throughput. Pre-LOE drugs generate more PA volume per patient because payers apply more aggressive step therapy and quantity limits, knowing the drug’s price will soon fall.<\/p>\n\n\n\n

    Using Patent Intelligence to Build Your Target List<\/strong><\/h2>\n\n\n\n

    There are more than 2,000 specialty drugs on the U.S. market, and their patent portfolios are complex. A single drug may have dozens of patents covering the compound, formulations, dosing regimens, manufacturing processes, and methods of treatment – each with a different expiration date. The relevant date for LOE risk is not the earliest patent expiry. It is the date by which a generic or biosimilar manufacturer can successfully launch. That depends on paragraph IV certifications, patent litigation outcomes, 180-day exclusivity grants, and FDA review timelines for ANDAs and BLAs.<\/p>\n\n\n\n

    This is where purpose-built patent intelligence platforms become operationally necessary. DrugPatentWatch tracks the full patent lifecycle for FDA-approved drugs, including Orange Book patent listings, paragraph IV certifications, litigation status, and projected LOE dates that account for the legal landscape rather than just the patent face date [6]. For a commercial vendor doing BD target prioritization, this means you can screen drugs by projected LOE date range, filter by therapeutic category, and cross-reference against specialty dispensing channel to identify which drugs are entering the pre-LOE window where manufacturer commercial investment is peaking.<\/p>\n\n\n\n

    A practical search workflow: screen for drugs with projected LOE in 24 to 48 months, filter to specialty-dispensed categories (biologics, rare disease, oncology, immunology, neurology), and sort by current annual net sales. The result is a prioritized list of drugs where the manufacturer commercial infrastructure is still fully funded and the vendor engagement window is open. That list becomes your BD targeting universe.<\/p>\n\n\n\n

    The Decision-Making Unit Inside a Specialty Pharmacy<\/strong><\/h2>\n\n\n\n

    Understanding who buys what is not complicated, but vendors consistently mismap the DMU and call on the wrong people. At a major PBM-owned specialty pharmacy, the decision architecture for vendor relationships looks roughly like this:<\/p>\n\n\n\n

    The VP or SVP of Specialty Pharmacy Operations owns the operational vendor relationships – technology integrations, workflow tools, and dispensing platform decisions. This person cares about throughput, accuracy, and compliance. They are not buying outcomes programs; they are buying reliability.<\/p>\n\n\n\n

    The VP of Clinical Programs or Chief Pharmacy Officer owns the clinical service layer – therapy management programs, adherence tools, and clinical data partnerships. This is the right entry point for vendors selling adherence technology, clinical support platforms, or outcomes measurement capabilities.<\/p>\n\n\n\n

    The VP of Manufacturer Relations or Payer Contracting owns the commercial program relationships – hub service coordination, copay assistance integrations, and limited distribution network agreements. If you are a hub service vendor or a copay administration platform, this person is your primary contact.<\/p>\n\n\n\n

    The Chief Data Officer or VP of Analytics owns data licensing and analytics partnerships. This is a newer role that has gained influence as specialty pharmacies have recognized their patient data as a commercial asset.<\/p>\n\n\n\n

    At independent and health system SPs, these roles collapse. One or two senior leaders often own all vendor relationships. That concentration makes access easier but can slow decision cycles when leadership bandwidth is constrained.<\/p>\n\n\n\n

    The Value Proposition That Actually Lands Pre-LOE<\/strong><\/h2>\n\n\n\n

    Most commercial and market access vendors make a critical error in their pre-LOE pitches: they lead with platform capabilities and follow with evidence of outcomes. Specialty pharmacy executives, particularly at the large PBM-owned SPs, see dozens of vendor pitches per quarter. Platform capabilities are table stakes.<\/p>\n\n\n\n

    What lands in pre-LOE conversations is revenue-cycle specificity. You need to show the specialty pharmacy exactly how your offering protects or expands their revenue on a specific drug that they can see entering competitive pressure.<\/p>\n\n\n\n

    For a copay assistance integration vendor, that means showing data on DIR fee recovery rates and specialty dispensing profitability for the drug in question, and demonstrating how your platform reduces the administrative overhead of managing copay program eligibility as that drug approaches LOE and copay program terms change.<\/p>\n\n\n\n

    For an adherence technology vendor, that means showing therapy persistence data for the relevant disease state and connecting therapy discontinuation rates to dispensing revenue loss per patient at the SP level.<\/p>\n\n\n\n

    For a hub services vendor, that means showing operational performance metrics from comparable disease states – PA approval cycle time, prior auth appeal success rates, time from prescription receipt to first fill – and directly connecting those metrics to the SP’s patient onboarding efficiency.<\/p>\n\n\n\n

    “Specialty pharmacy revenue per patient on a branded biologic can exceed $8,000 to $12,000 per year in dispensing fees and service reimbursements; when a biosimilar enters the market, that revenue can compress by 40 to 60 percent within 18 months.”<\/p>\n\n\n\n

    – Adam J. Fein, Drug Channels Institute, 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers [2]<\/em><\/p>\n\n\n\n

    Identifying the Right Drugs: A Pre-LOE Screening Framework<\/strong><\/h2>\n\n\n\n

    When you build your BD target list from patent intelligence, the most useful filters are not just LOE date and revenue. Disease state commercial complexity is a better signal for vendor opportunity. High-complexity disease states for commercial vendors are those where:<\/p>\n\n\n\n

      \n
    • Patient support needs are clinical, not just logistical – rare autoimmune conditions, rare hematologic disorders, MS, and neuromuscular disease require far more vendor-supported touchpoints per patient than standard chronic conditions.<\/li>\n\n\n\n
    • Payer prior authorization burden is high and frequent – oncology oral oncolytics, biologics for inflammatory conditions, and gene therapies generate substantially more PA transactions per patient than standard specialty drugs.<\/li>\n\n\n\n
    • Adherence risk is clinically significant and measurable – chronic conditions with symptom-free periods create discontinuation risk, and conditions where non-adherence has measurable clinical consequences generate the highest demand for adherence programs.<\/li>\n\n\n\n
    • Limited distribution is standard – drugs with REMS requirements, fragile cold-chain biologics, and drugs requiring patient monitoring concentrate dispensing in a small network where vendor relationships matter most.<\/li>\n<\/ul>\n\n\n\n

      Drugs matching these criteria generate the largest volume of commercial activity – copay assistance transactions, PA appeals, clinical check-in calls, dispensing data reporting – and therefore the largest opportunity for vendors whose revenue depends on those transactions.<\/p>\n\n\n\n

      DrugPatentWatch allows you to filter by drug category and cross-reference with FDA REMS program information and specialty pharmacy channel designation from manufacturer prescribing information. A vendor with this intelligence can rank its target universe not just by LOE date and revenue, but by the operational complexity that drives vendor spend.<\/p>\n\n\n\n

      Case Study: Immunology Biologic Approaching LOE<\/strong><\/h2>\n\n\n\n

      Consider a scenario that reflects a common real-world pattern.<\/p>\n\n\n\n

      A large-molecule biologic for moderate-to-severe plaque psoriasis has been commercially available for eight years. It generates approximately $2.1 billion in U.S. net sales annually. It is distributed through a limited network of six specialty pharmacies, including two large PBM-owned SPs and four category-specialist independents. The manufacturer runs a robust hub program and a commercial copay program that caps patient out-of-pocket costs at $5 per month.<\/p>\n\n\n\n

      Patent intelligence from DrugPatentWatch shows that the compound patent expires in 26 months and that two biosimilar manufacturers have already filed ANDAs with paragraph IV certifications and are currently in litigation. Based on historical precedent in the biologic LOE space, the projected market entry timeline for a biosimilar competitor is 18 to 24 months.<\/p>\n\n\n\n

      For a commercial vendor doing BD planning, this scenario creates four specific opportunities:<\/p>\n\n\n\n

        \n
      • The manufacturer’s commercial team is running at maximum funding and is highly motivated to demonstrate program ROI before LOE – making them receptive to vendor partnerships that improve documented outcomes.<\/li>\n\n\n\n
      • The specialty pharmacies in the limited distribution network are dispensing at peak volume and actively evaluating their operational infrastructure.<\/li>\n\n\n\n
      • The hub program will almost certainly be restructured or competitively rebid within 18 to 24 months.<\/li>\n\n\n\n
      • The copay assistance program will change materially at biosimilar entry, creating operational transition work that rewards well-positioned vendors.<\/li>\n<\/ul>\n\n\n\n

        A vendor who identifies this drug today and begins outreach to the specialty pharmacy network has a realistic 12 to 18 month window to establish operational credibility before the manufacturer rebid process begins. That credibility, documented in performance data, is the primary competitive asset in any subsequent manufacturer or SP RFP.<\/p>\n\n\n\n

        Case Study: Rare Disease Enzyme Replacement Therapy<\/strong><\/h2>\n\n\n\n

        A different dynamic plays out in rare disease. An enzyme replacement therapy for a lysosomal storage disorder treats fewer than 5,000 U.S. patients annually but generates $800 million in net sales due to extreme per-patient pricing. Distribution is ultra-limited: two specialty pharmacies have network status, both health system SPs with embedded metabolic disease programs.<\/p>\n\n\n\n

        The LOE profile is different here. Biosimilar development for complex enzymes is technically difficult, and market entry timelines are longer than for monoclonal antibodies. But the manufacturer has a successor product in Phase III clinical trials – a more stable formulation with a longer infusion interval – and has already begun planning the commercial infrastructure for the new product.<\/p>\n\n\n\n

        For a vendor focused on rare disease patient support, the opportunity is not driven by patent expiration risk on the current product. It is driven by the manufacturer’s need to build a successor program. The specialty pharmacies currently serving this patient population will be the preferred distribution partners for the successor product. A vendor already embedded with those SPs – providing, for example, a disease-specific adherence monitoring platform – has direct access to the reference relationships that will influence the manufacturer’s hub and SP network selection for the new product.<\/p>\n\n\n\n

        This illustrates the second reason to target specialty pharmacies pre-LOE: it is not only about protecting revenue on the expiring drug. It is about positioning for what comes next.<\/p>\n\n\n\n

        Business Development Tactics That Work<\/strong><\/h2>\n\n\n\n

        The tactical playbook for pre-LOE specialty pharmacy BD has four elements that work in combination:<\/p>\n\n\n\n

        Patent Intelligence-Led Prospecting<\/strong><\/h4>\n\n\n\n

        Use DrugPatentWatch or a comparable platform to identify drugs entering the 18-to-36-month pre-LOE window in your target therapeutic categories. For each drug, map the specialty pharmacy distribution network. The manufacturer’s prescribing information will list SPs in a limited distribution network if one exists; for broadly distributed drugs, analyze NDC-level dispensing data from commercially available claims databases to identify the highest-volume dispensing SPs.<\/p>\n\n\n\n

        Disease-State Operational Expertise as Your Entry Point<\/strong><\/h4>\n\n\n\n

        When you cold-call a specialty pharmacy VP on a new drug, your credibility is zero. When you call specifically about the commercial program around a drug you know they are dispensing – and you can demonstrate operational knowledge of that drug’s prior authorization profile, its copay program structure, and the clinical support protocols its hub vendor is running – your credibility is immediately higher. Build disease-state expertise into your BD team’s preparation before outreach begins.<\/p>\n\n\n\n

        Reference-Driven Introductions<\/strong><\/h4>\n\n\n\n

        Reference-driven introductions are more efficient than cold outreach. If you have an existing relationship with a manufacturer whose drug is distributed through a target SP, ask for a warm introduction. Manufacturers want their SP network and hub vendors working well together; a vendor who proactively builds that collaboration has a clearer commercial story for the next manufacturer RFP.<\/p>\n\n\n\n

        Data and Benchmarking as Lead Generation<\/strong><\/h4>\n\n\n\n

        Specialty pharmacies want to know how their performance on a given drug or disease state compares to peers. If you have aggregate, de-identified benchmarking data on copay utilization rates, PA approval timelines, or therapy persistence across a disease category, offering that benchmark data as a conversation-starter converts what would otherwise be a cold vendor pitch into a consultative conversation the SP has a reason to attend.<\/p>\n\n\n\n

        What Vendors Get Wrong<\/strong><\/h2>\n\n\n\n

        The most common BD mistake in this space is pitching the platform before establishing context. Specialty pharmacy executives are not impressed by demos of technology features they cannot immediately connect to their current operational challenges and revenue risks.<\/p>\n\n\n\n

        The second most common mistake is ignoring the manufacturer relationship. Specialty pharmacies do not evaluate vendors in isolation. They evaluate vendors in the context of the manufacturer commercial programs they participate in. If your platform is not compatible with the data reporting standards of the major hub vendors the SP’s key manufacturer partners use, your operability score is low regardless of your clinical outcomes data.<\/p>\n\n\n\n

        The third mistake is treating all drugs approaching LOE as equivalent opportunities. Drugs with complex, high-service commercial programs – where the SP earns meaningful service fees from the manufacturer for clinical support activity – are much more valuable target contexts than drugs with thin commercial programs where the SP is primarily earning dispensing margin.<\/p>\n\n\n\n

        The fourth mistake is ignoring the post-LOE successor opportunity when it exists. In therapeutic categories where the manufacturer has a pipeline asset in the same disease area, the commercial infrastructure for the successor product will be built on the relationships formed during the predecessor drug’s commercial lifecycle. Vendors who perform well on the current product are in the strongest position to win the successor program.<\/p>\n\n\n\n

        Building a Pre-LOE BD Pipeline: Practical Steps<\/strong><\/h2>\n\n\n\n

        Here is a concrete operating sequence for a commercial or market access vendor building a pre-LOE SP BD pipeline:<\/p>\n\n\n\n

          \n
        1. Start with patent intelligence. Using DrugPatentWatch, screen for FDA-approved drugs with projected LOE in 18 to 48 months. Filter to your target therapeutic areas. For each drug, note current annual net sales, the number of approved biosimilar or generic ANDAs filed, and whether litigation is ongoing. Drugs with active paragraph IV litigation and a high probability of eventual biosimilar entry are your priority targets.<\/li>\n\n\n\n
        2. Build a distribution map. For each priority drug, identify the specialty pharmacy distribution network. Cross-reference the drug’s prescribing information for limited distribution designation; if the drug is broadly distributed, use claims data to identify the highest-volume dispensing SPs.<\/li>\n\n\n\n
        3. Map the commercial program structure. Review the drug’s patient support program – is there a dedicated hub program? A commercial copay assistance program? A clinical support protocol? The more complex the commercial program, the larger the vendor opportunity.<\/li>\n\n\n\n
        4. Identify the DMU at each SP. LinkedIn, industry conference attendance records, and NASP membership directories all provide contact-level intelligence on SP leadership roles.<\/li>\n\n\n\n
        5. Build a specific value proposition for each SP based on their current role in the drug’s commercial program and the specific revenue risk they face at LOE.<\/li>\n\n\n\n
        6. Execute outreach with disease-state specificity. Your first contact message should reference the specific drug, the SP’s role in its distribution, and a concrete question or benchmark that demonstrates your operational knowledge.<\/li>\n<\/ol>\n\n\n\n

          The Post-LOE Reality: What Happens If You Wait<\/strong><\/h2>\n\n\n\n

          If you begin specialty pharmacy BD outreach after LOE rather than before it, you are competing in a fundamentally different market.<\/p>\n\n\n\n

          Post-LOE, manufacturer commercial program budgets have contracted. Hub program fee structures are lower. Copay assistance programs have either ended or converted to income-based PAPs with much lower per-patient costs to the manufacturer. The commercial infrastructure that funds vendor relationships has shrunk.<\/p>\n\n\n\n

          The specialty pharmacy, meanwhile, has shifted its operational priorities. Its dispensing volume on the branded product has likely declined. If a biosimilar launched, the SP is now in a dispensing margin competition between the branded and biosimilar versions, and its primary operational focus is managing that transition efficiently, not adopting new programs.<\/p>\n\n\n\n

          Post-LOE new vendor introductions are evaluated against a lower budget ceiling and a higher skepticism threshold. The value proposition has to be dramatically stronger because the SP is no longer operating in the context of a high-revenue program that funds operational experimentation.<\/p>\n\n\n\n

          Specialty pharmacies cycle through vendors continuously, and operational performance failures create openings at any stage of a drug’s commercial lifecycle. But the structural advantage clearly belongs to the vendor who arrives pre-LOE with a clear program-specific story, an established disease-state credential, and the patent intelligence to know exactly when the window is open.
          <\/p>\n\n\n\n

          Key Takeaways<\/strong><\/h2>\n\n\n\n

          \u2022  The 18-to-36-month period before a drug loses exclusivity is when manufacturer commercial programs are fully funded, SP relationships are actively managed, and successor program planning begins. This is the BD window that matters most.<\/p>\n\n\n\n

          \u2022  Patent intelligence platforms like DrugPatentWatch give commercial vendors a concrete, actionable way to identify which drugs are entering this window and build a prioritized target list from projected LOE dates, drug revenue, and disease-state commercial complexity.<\/p>\n\n\n\n

          \u2022  Specialty pharmacies are not a monolithic market. The four-tier structure (PBM-owned majors, health system SPs, independent category specialists, and physician office dispensing) requires different entry strategies and value propositions for each tier.<\/p>\n\n\n\n

          \u2022  The decision-making unit at a specialty pharmacy is segmented by function. Vendors calling on the wrong role will generate activity but not pipeline. Map the DMU before the first outreach call.<\/p>\n\n\n\n

          \u2022  The most effective pre-LOE BD pitches lead with disease-state revenue risk and documented operational impact, not platform features.<\/p>\n\n\n\n

          \u2022  The four common tactical mistakes are preventable: late-stage entry, platform-first pitching, LOE-agnostic targeting, and ignoring the successor program opportunity.<\/p>\n\n\n\n

          \u2022  The vendor who shows up 24 months before LOE, with patent data in hand and a specific conversation about the drug the SP is currently dispensing, is competing for the full commercial lifecycle of what comes next.
          <\/p>\n\n\n\n

          FAQ<\/strong><\/h2>\n\n\n\n

          Q1: How do I identify which specialty pharmacies are in the limited distribution network for a drug I am targeting?<\/strong><\/h3>\n\n\n\n

          Start with the drug’s FDA-approved prescribing information. Manufacturers with limited distribution drugs are required to list network pharmacies in the ‘How Supplied\/Storage and Handling’ section or in a dedicated REMS section of the label, or on the program’s patient access website. For broadly distributed drugs, CMS Part D claims data (available through CMS drug utilization research files) and commercially licensed claims databases from vendors like IQVIA, Symphony Health, or Komodo Health provide NDC-level dispensing volume by dispensing entity. Combining label review with claims data gives you both the official network list and the volume distribution within it.<\/p>\n\n\n\n

          Q2: DrugPatentWatch shows multiple patent expiry dates for the same drug. Which one is the actual LOE date to use for BD planning?<\/strong><\/h3>\n\n\n\n

          The operative date is the last unexpired Orange Book-listed patent date, modified by litigation outcomes and any applicable regulatory exclusivity periods – orphan drug exclusivity, pediatric exclusivity, or new chemical entity exclusivity. DrugPatentWatch consolidates this and displays a projected LOE date that accounts for the legal landscape [6]. For BD planning purposes, the most useful signal is whether an ANDA or BLA has been filed with a paragraph IV certification. That indicates a generic or biosimilar manufacturer has made an affirmative decision to challenge the patent. The certification date is more operationally predictive than the face date on any individual patent.<\/p>\n\n\n\n

          Q3: Our vendor platform serves manufacturers, not specialty pharmacies. Why should we care about pre-LOE SP BD at all?<\/strong><\/h3>\n\n\n\n

          Because manufacturer procurement decisions are heavily influenced by specialty pharmacy operational preferences. In an RFP for a hub services program, a manufacturer will ask their preferred SP network which hub vendors they have the cleanest operational integration with and the highest PA approval efficiency. A vendor with no operational footprint in the SPs serving the disease category of interest cannot provide this reference. Pre-LOE SP engagement is not just a specialty pharmacy sales strategy. It is manufacturer sales enablement.<\/p>\n\n\n\n

          Q4: How do we handle outreach to a specialty pharmacy owned by a PBM that competes with our manufacturer clients?<\/strong><\/h3>\n\n\n\n

          This is a real and growing tension as the PBM-owned specialty pharmacies (Accredo, CVS Specialty, AllianceRx) also function as formulary decision-makers for the same payers determining coverage for your manufacturer clients’ drugs. The practical answer is to separate the commercial program conversation from the payer relations conversation. SP operations teams at PBM-owned SPs manage their dispensing program vendor relationships independently of the PBM’s formulary team, and they are evaluated on operational metrics, not formulary outcomes. Keep BD conversations explicitly focused on operational efficiency and patient outcomes within commercial programs that already have payer coverage.<\/p>\n\n\n\n

          Q5: What is a realistic timeline from first outreach to a signed agreement with a major specialty pharmacy?<\/strong><\/h3>\n\n\n\n

          For a large PBM-owned specialty pharmacy, budget 12 to 18 months from first substantive contact to executed agreement. The procurement cycle at these organizations is formalized, involves legal review, and requires IT security assessment for any technology integration. Health system specialty pharmacies operate on similar timelines but may move faster if you can navigate through a physician champion in the relevant disease service line. Independent specialty pharmacies can close in 6 to 9 months because decision-making is more concentrated and procurement is less bureaucratic. The implication for pre-LOE targeting: if a drug has 24 months to projected LOE, you have exactly enough time to close a deal with a large SP if you begin today. Waiting six months makes that timeline extremely tight.
          <\/p>\n\n\n\n

          References<\/strong><\/h2>\n\n\n\n

          [1] IQVIA Institute for Human Data Science. (2023). The Use of Medicines in the U.S. 2023: Usage and Spending Trends and Outlook to 2027. IQVIA Institute. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-use-of-medicines-in-the-us-2023<\/p>\n\n\n\n

          [2] Fein, A. J. (2024). 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Drug Channels Institute. https:\/\/www.drugchannels.net\/2024\/03\/the-2024-economic-report-on-us.html<\/p>\n\n\n\n

          [3] U.S. Food and Drug Administration. (2024). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/<\/p>\n\n\n\n

          [4] Avalere Health. (2023). Specialty Pharmacy Trends in Limited Distribution Drug Networks. Avalere Health. https:\/\/www.avalere.com\/insights\/specialty-pharmacy-limited-distribution<\/p>\n\n\n\n

          [5] National Association of Specialty Pharmacy (NASP). (2023). Specialty Pharmacy Industry Almanac 2023. NASP. https:\/\/www.naspnet.org<\/p>\n\n\n\n

          [6] DrugPatentWatch. (2024). Drug patent expiration tracking and LOE analysis tools. DrugPatentWatch. https:\/\/www.drugpatentwatch.com<\/p>\n","protected":false},"excerpt":{"rendered":"

          The Clock You Are Ignoring Every branded drug in the specialty channel has an expiration date that has nothing to […]<\/p>\n","protected":false},"author":1,"featured_media":37305,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37304"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37304\/revisions"}],"predecessor-version":[{"id":37306,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37304\/revisions\/37306"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37305"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}